Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7846908 RNAi modulation of TGF-beta and therapeutic uses thereof

Patent 7846908 was granted and assigned to Alnylam Pharmaceuticals on December, 2010 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Current Assignee

Alnylam Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Rainer Constien0

Hans-Peter Vornlocher0

Pamela Tan0

Date of Patent

December 7, 2010

0

Patent Application Number

117247900

Date Filed

March 15, 2007

0

Patent Primary Examiner

0

Patent abstract

The present invention concerns methods of treatment using transforming growth factor beta (TGF-beta) modulators. More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling, by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7846908 RNAi modulation of TGF-beta and therapeutic uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.